Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Clinical data from an investigator initiated clinical trial of combination of LD IL-2 and CTLA 4 IG will be reported and will support the planned phase 2b trial of COYA 302 n FTD.” As of ...

Coya CMO, Dr. Fred Grossman said, “As we have indicated in the past, we expect 2025 to hold important milestones for the Company, including initiating the phase 2b trial of COYA 302, which is the ...

英文题目：Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? 中文题目：难治性类风湿关节炎：我们已经知道什么，还需要学习什么？ 类风湿关节炎（RA）是最常见的炎症性关节疾病，严重影响患者的生活质量和社会参与能力。自本世纪 ...

With the use of T cell receptor T cells (TCR-T cells) and chimeric antigen receptor T cells (CAR-T cells), T-cell immunotherapy for cancer has advanced significantly in recent years. CAR-T cell ...